These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37434878)

  • 1. Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4.
    Centonze D; Amato MP; Brescia Morra V; Cocco E; De Stefano N; Gasperini C; Gallo P; Pozzilli C; Trojano M; Filippi M
    Ther Adv Neurol Disord; 2023; 16():17562864231183221. PubMed ID: 37434878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4.
    Meuth SG; Bayas A; Kallmann B; Linker R; Rieckmann P; Wattjes MP; Mäurer M; Kleinschnitz C
    Expert Opin Pharmacother; 2022 Sep; 23(13):1503-1510. PubMed ID: 35930260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
    Meuth SG; Bayas A; Kallmann B; Kleinschnitz C; Linker R; Rieckmann P; Mäurer M
    Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates.
    Inshasi JS; Alfahad S; Alsaadi T; Hassan A; Zein T; Mifsud VA; Nouri SI; Shakra M; Shatila AO; Szolics M; Thakre M; Kumar A; Boshra A
    Neurol Ther; 2021 Dec; 10(2):435-454. PubMed ID: 33891277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence.
    Oreja-Guevara C; Brownlee W; Celius EG; Centonze D; Giovannoni G; Hodgkinson S; Kleinschnitz C; Havrdova EK; Magyari M; Selchen D; Vermersch P; Wiendl H; Van Wijmeersch B; Salloukh H; Yamout B
    Mult Scler Relat Disord; 2023 Jan; 69():104459. PubMed ID: 36565573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
    Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
    Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
    Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers.
    Habek M; Drulovic J; Brecl Jakob G; Barbov I; Radulovic L; Rajda C; Rejdak K; Turčáni P
    Neurol Ther; 2023 Feb; 12(1):25-37. PubMed ID: 36394714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
    Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
    Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cladribine Tablets and Relapsing-Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know.
    AlJumah M; Alkhawajah MM; Qureshi S; Al-Thubaiti I; Ayoub O; Bohlega SA; Bushnag A; Cupler E; Daif A; El Boghdady A; Hassan A; Al Malik Y; Saeedi J; Al-Shamrany F; Shosha E; Rieckmann P
    Neurol Ther; 2020 Jun; 9(1):11-23. PubMed ID: 32056129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
    Meuth SG; Ruck T; Aktas O; Hartung HP
    Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice.
    Stangel M; Becker V; Elias-Hamp B; Havla J; Grothe C; Pul R; Rau D; Richter S; Schmidt S
    Mult Scler Relat Disord; 2021 Sep; 54():103075. PubMed ID: 34261026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
    Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.
    Giovannoni G; Mathews J
    Neurol Ther; 2022 Jun; 11(2):571-595. PubMed ID: 35318617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
    Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; Verdun di Cantogno E
    Mult Scler; 2023 May; 29(6):719-730. PubMed ID: 37012898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
    Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist TP; Coyle PK; Dangond F; Alexandri N; Galazka A
    Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.